BeiGene
ONC
#683
Rank
S$38.22 B
Marketcap
$336.89
Share price
2.82%
Change (1 day)
71.73%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (ONC) - Total liabilities

Total liabilities on the balance sheet as of December 2024 : S$3.40 Billion

According to BeiGene 's latest financial reports the company's total liabilities are S$3.40 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2024-12-31S$3.51 B17.48%
2023-12-31S$2.99 B11.94%
2022-12-31S$2.67 B-17.63%
2021-12-31S$3.24 B41.82%
2020-12-31S$2.29 B168.02%
2019-12-31S$0.85 B26.12%
2018-12-31S$0.67 B39.87%
2017-12-31S$0.48 B532.76%
2016-12-31S$76.57 M27.53%
2015-12-31S$60.03 M63.14%
2014-12-31S$36.8 M-42.51%
2013-12-31S$64.01 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
S$15.98 M-99.53%๐Ÿ‡บ๐Ÿ‡ธ USA
S$1.09 B-67.75%๐Ÿ‡บ๐Ÿ‡ธ USA